Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHLOE pancreas: Cholesterol Metabolism Reprogramming in Pancreatic Adenocarcinoma
NCT04862260Phase 1Active, not recruiting
- Sponsor
- CHU de Québec-Université Laval
- Start
- Oct 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of atorvastatin, ezetimibe and evolocumab in pancreatic ductal adenocarcinoma (PDAC), sponsored by CHU de Québec-Université Laval. Primary endpoints: Adverse Events at 2 years and Dose-Limiting Toxicities at 2 years. Started Oct 2021; status: active, not recruiting.
02
Drugs
atorvastatinezetimibeevolocumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04862260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04862260.